LANGERHANS CELL HISTIOCYTOSIS (LCH)
Clinical trials for LANGERHANS CELL HISTIOCYTOSIS (LCH) explained in plain language.
Never miss a new study
Get alerted when new LANGERHANS CELL HISTIOCYTOSIS (LCH) trials appear
Sign up with your email to follow new studies for LANGERHANS CELL HISTIOCYTOSIS (LCH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Old drug, new hope: lenalidomide tackles rare histiocyte cancers
Disease control OngoingThis phase 2 study tests the chemotherapy drug lenalidomide (Revlimid) in 12 adults with one of three rare histiocyte disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, or histiocytic sarcoma. The goal is to see how many patients achieve disease control or remissi…
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS (LCH)
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for rare cancer: drug cocktail targets stubborn LCH
Disease control OngoingThis phase 2 trial tests a combination of three drugs—selinexor, thalidomide, and dexamethasone—in 40 adults with relapsed or refractory Langerhans cell histiocytosis (LCH), a rare immune cell disorder. The goal is to see if the XTD regimen can shrink tumors and delay disease pro…
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS (LCH)
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Scientists hunt for genetic clues in rare blood disorders
Knowledge-focused TerminatedThis study looks at the genetic makeup of rare blood diseases like Castleman disease and Langerhans cell histiocytosis. Researchers will analyze blood or tissue samples from 135 participants to find genetic changes that could be targeted by existing or experimental therapies. The…
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS (LCH)
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC